Venus Remedies Limited - Asset Resilience Ratio
Venus Remedies Limited (VENUSREM) has an Asset Resilience Ratio of 30.75% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See VENUSREM working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2025)
This chart shows how Venus Remedies Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see VENUSREM total assets.
Liquid Assets Composition Over Time
This chart breaks down Venus Remedies Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Venus Remedies Limited (VENUSREM) long-term investment share to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs219.90 Million | 2.86% |
| Short-term Investments | Rs2.14 Billion | 27.89% |
| Total Liquid Assets | Rs2.36 Billion | 30.75% |
Asset Resilience Insights
- Very High Liquidity: Venus Remedies Limited maintains exceptional liquid asset reserves at 30.75% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Venus Remedies Limited Industry Peers by Asset Resilience Ratio
Compare Venus Remedies Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for Venus Remedies Limited (2006–2025)
The table below shows the annual Asset Resilience Ratio data for Venus Remedies Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 21.84% | Rs1.56 Billion ≈ $16.90 Million |
Rs7.16 Billion ≈ $77.40 Million |
+8.47pp |
| 2024-03-31 | 13.37% | Rs838.05 Million ≈ $9.06 Million |
Rs6.27 Billion ≈ $67.79 Million |
+1.38pp |
| 2023-03-31 | 11.99% | Rs720.75 Million ≈ $7.79 Million |
Rs6.01 Billion ≈ $65.00 Million |
+4.18pp |
| 2022-03-31 | 7.81% | Rs453.11 Million ≈ $4.90 Million |
Rs5.80 Billion ≈ $62.71 Million |
+2.55pp |
| 2021-03-31 | 5.26% | Rs292.55 Million ≈ $3.16 Million |
Rs5.56 Billion ≈ $60.11 Million |
+4.94pp |
| 2020-03-31 | 0.32% | Rs20.42 Million ≈ $220.88K |
Rs6.38 Billion ≈ $68.97 Million |
+0.01pp |
| 2019-03-31 | 0.31% | Rs23.01 Million ≈ $248.80K |
Rs7.33 Billion ≈ $79.25 Million |
-0.65pp |
| 2018-03-31 | 0.96% | Rs72.21 Million ≈ $780.93K |
Rs7.51 Billion ≈ $81.20 Million |
-7.66pp |
| 2017-03-31 | 8.63% | Rs715.21 Million ≈ $7.73 Million |
Rs8.29 Billion ≈ $89.67 Million |
+8.30pp |
| 2006-03-31 | 0.33% | Rs2.04 Million ≈ $22.07K |
Rs622.28 Million ≈ $6.73 Million |
-- |
About Venus Remedies Limited
Venus Remedies Limited engages in the pharmaceutical business in India and internationally. It is involved in the research and development of solutions focusing on antimicrobial resistance and oncology. The company also offers analgesic, analgesic and antipyretic, antibiotic, anticoagulant, antiemetic, antiviral, cardiovascular, disinfectant and antiseptic, gastro therapy, hepatoprotective, hormo… Read more